Objective: The purpose was to study the therapeutic effect of Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum aspiration and lavage on ICU patients with severe pneumonia, and analyze its effect on serum infection indexes and inflammatory factors.Methods: 100 patients with severe pneumonia admitted to ICU of our hospital from January 2018 to December 2019 were randomly selected and divided into control group and experimental group by drawing lots, with 50 cases in each group. The patients in the control group were treated with antibiotics combined with fiberoptic bronchoscope sputum aspiration and lavage while the experimental group was treated with Xuebijing on the basis of the control group to compare the treatment effective rates, incidence of adverse reactions, serum infection indexes (CRP and PCT) and inflammatory factors (IL-6 and IL-8) after treatment between the two groups.Results: The treatment effective rate in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P<0.05). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P<0.05). The CRP and PCT expression levels in the experimental group were significantly lower than those in the control group after treatment, with statistically significant differences (P<0.05). After treatment, the IL-6 and IL-8 expression levels in the experimental group were significantly lower than those in the control group, with statistically significant differences (P<0.05).Conclusion: Xuebijing combined with antibiotics and fiberoptic bronchoscope sputum aspiration and lavage has better therapeutic effect on ICU patients with severe pneumonia, which can significantly reduce the expression levels of serum infection indexes and inflammatory factors in patients with severe pneumonia, with high clinical application value.

Abstract The chronic kidney disease (CKD) patients may have a variety of complications during receiving peritoneal dialysis (PD). The malnutrition in CKD patients is related to their lower life quality, higher hospitalization rates, and higher risk of cardiovascular disease, as well as the increased morbidity and mortality. Hence, it is very important to monitor and then manage the nutritional status of CKD patients. Thus, we perform this randomized controlled study protocol to introduce a continuing nursing program based on Omaha system (OS) for the patients with CKD receiving PD treatment. The randomized trial will be implemented from November 2020 to May 2021 and was granted through the Research Ethics Committee of Wuhan No.1 Hospital (2020003281). Two hundred patients meet inclusion criteria and exclusion criteria are included. Patients who meet the following criteria will be selected: voluntary participation, aged 20 to 60; undergoing the regular PD treatment for at least 3 months. Patients will be excluded if the patients are in unstable status, or experience the intermittent PD or some other kinds of dialysis mode, have severe cachexia, infection, or malnutrition, or if they have mental disorders. In control group, patients are given routine treatment, containing general guidance associated with PD and the outpatient telephone calls from the clinical nurses during follow-up. In study group, the patients are given the continuous nursing treatment scheme based on OS. The clinical results are the biochemical parameters after intervention, anthropometry, as well as the subjective global assessment. Table 1 reveals the clinical endpoints between the 2 groups. This protocol can guide nurses to develop a nursing program based on evidence for patients with CKD receiving PD. Trial registration: This study protocol was registered in Research Registry (researchregistry6202).

Although the incidence of lung cancer is increasing worldwide, the molecular mechanisms for its tumorigenesis, progression and prognosis remain unknown. As a member of the tumor necrosis factor superfamily, vascular endothelial growth inhibitor (VEGI) is involved in the development and progression of many malignant diseases. In the present study, the expression of VEGI and CD31 was examined via immunohistochemistry in non-small cell lung cancer (NSCLC) tissues obtained from 150 patients with NSCLC. The inhibitory effect of VEGI on tumor-associated blood vessel formation and growth was investigated by determining the relationship between VEGI protein expression and microvascular density (MVD). Prognostic significance was evaluated using the Kaplan-Meier method. VEGI expression was downregulated or lost in 68.7% (103/150) of patients with NSCLC, an effect that was more prevalent in adenocarcinoma (AC), 76.0% (57/75), than in squamous cell carcinoma, 61.3% (46/75). A significant negative correlation was indentified between VEGI expression and lymphovascular invasion (P=0.039) and lymph node metastasis (P=0.017) in AC tissue. Additionally, MVD was significantly lower in the VEGI-rich group compared with the VEGI-poor group. The downregulation of VEGI expression was also associated with poorer overall survival (P=0.011) in patients with AC. The present study therefore provides evidence that VEGI may be a new and effective prognostic marker of lung AC.

•Meta-analysis of MMP-9 polymorphism and digestive cancers susceptibility•Provides a systematic summary of the last 20 years of research findings•20 studies with 3201 cases and 4301 controls were included.•MMP-9 −1562 C/T polymorphism might increase digestive cancers susceptibility.